There is considerable genetical and pharmacological evidence showing that the mere 1.5-fold overexpression of DYRK1A is responsible for most cognitive deficits observed in DS patients (reviews: [14,87,88,89,90,91,92]). The gene discussed is DYRK1A; the disease is Cognitive impairment.